Biomarker: p27

Histology type: endometrioid endometrial carcinoma

Stage: early stage

Country: Japan

Region: Sagamihara

Study type: prospective study

Followed up time :

Conclusion: p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.

Sample type : tissue

Sample method: RT-PCR/immunohistochemistry

Expression pattern : strongly positive staining

Expression elevation: The specific staining of p27 was identified by brown coloredorcoloed products in the nucleus. Endometrial carcinoma cells revealed variations in staining intensity. Consequently, we classified the intensity into two groups: strongly positive (SP) and positive group, in addition to a negative group. Endometrial positive nuclei, including the SP and positive staining, as positive LI (P LI). During and after MPA therapy, the results of p27 LIs were averaged every 6 weeks, and p27 LIs were compared between the effective and noneffective groups in the clinical course.

Statictics: Mean ;Range

Cohort age: 30;24–38

Funtion Uniprot: Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry

UniProt ID: P46527

UniProt Link: https://www.uniprot.org/uniprotkb/P46527/entry

Biological function from UniProt: #Cell cycle

Molecular function from UniProt:

Tissue specificity from UniProt: Expressed in kidney (at protein level) (PubMed:15509543). Expressed in all tissues tested (PubMed:8033212). Highest levels in skeletal muscle, lowest in liver and kidney (PubMed:8033212).

Subcellular UniProt: #Cytoplasm #Endosome #Nucleus

Alternative name from UniProt:

Miscellaneous: Decreased levels of p27Kip1, mainly due to proteasomal degradation, are found in various epithelial tumors originating from lung, breast, colon, ovary, esophagus, thyroid and prostate.

Recommended name: Cyclin-dependent kinase inhibitor 1B

Gene name from HGNC: CDKN1B (KIP1, P27KIP1)

HPA class: Cancer-related genes Disease related genes Human disease related genes

AlphaFold DB: P46527

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P46527

Induction: Maximal levels in quiescence cells and early G1. Levels decrease after mitogen stimulation as cells progress toward S-phase.

HPA link: https://www.proteinatlas.org/ENSG00000111276-CDKN1B

Tissue specificity RNA from HPA: Low tissue specificity

Tissue expression from HPA: Cytoplasmic and nuclear expression in most tissues.

Single cell type specificity Cell type enhanced (Muller glia cells)

Immune cell specificity: Low human brain regional specificity

Subcellular summary HPA Located in Nucleoplasm, Vesicles (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in liver cancer (unfavorable), colorectal cancer (favorable) and renal cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000111276-CDKN1B/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000111276-CDKN1B/pathology/endometrial+cancer

Phenotype ID: 610755

Disease: Multiple endocrine neoplasia 4 (MEN4)

Note1: The disease is caused by variants affecting the gene represented in this entry

OMIM: 600778

OMIM link1: https://www.omim.org/entry/610755

OMIM link2: https://www.omim.org/entry/600778

HGNC ID: HGNC:1785

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1785